Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease

Table 2 Protein list

Gene symbol	Protein identification	Measured peptides	MASCOT score	BH adjusted p-value	Fold change
VTN	Vitronectin	6	391	0.02	-2.7
KNG1	Kininogen-1	2	115	0.02	1.4
THBS1	Thrombospondin-1	5	343	0.02	3.0
PON1	Serum paraoxonase/arylesterase 1	3	166	0.02	-1.6
PLG	Plasminogen	8	545	0.02	1.5
F5	Coagulation factor V	4	210	0.03	1.8
F2	Prothrombin	10	722	0.03	1.8
AMBP	Protein AMBP	2	124	0.04	2.4
APOB	Apolipoprotein B-100	4	1640	0.04	2.2
PROS1	Vitamin K-dependent protein S	3	198	0.04	2.0
CFHR1	Complement factor H-related protein 1	2	171	0.04	1.8
TTR	Transthyretin	2	163	0.04	-2.2
PF4	Platelet factor 4	2	186	0.04	1.4
SERPINA1	Alpha-1-antitrypsin	3	247	0.04	2.4
AHSG	Alpha-2-HS-glycoprotein	5	454	0.04	3.5
FN1	Fibronectin	7	567	0.05	-4.5
HRG	Histidine-rich glycoprotein	2	97	0.05	3.0
TF	Serotransferrin	2	195	0.05	3.2
IGHG2	Ig gamma-2 chain C region	3	214	0.05	2.0
ALB	Serum albumin	4	311	0.05	3.6
C1S	Complement C1s subcomponent	2	112	0.05	2.6
IGHM	Ig mu chain C region	4	265	0.05	-2.7
C4A	Complement C4-A	5	310	0.05	-2.8
A2M	Alpha-2-macroglobulin	2	157	0.05	3.3

List of differentially expressed proteins comparing no bone disease to high bone disease. The table includes information on gene symbol, protein identification, measured peptides (used for quantitation), confidence score (MASCOT), Benjamini-Hochberg adjusted p-value and fold-change (- indicates a protein is decreased in abundance in no bone disease compared to high bone disease, all other proteins are increased in abundance in no bone disease compared to high bone disease). A total of 10 patient serum samples with no bone disease and 10 patient serum samples with high bone disease were used during the discovery phase analysis.

ISSN: 1471-2164